Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule), Biologics (API, FDF), Packaging & Labelling, Fill-finish), Molecule (Small, Large (ADC, CGT)) - Global Forecast to 2030

1 INTRODUCTION 42 1.1 STUDY OBJECTIVES 42 1.2 MARKET DEFINITION 42 1.3 STUDY SCOPE 42 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 43 1.3.2 INCLUSIONS AND EXCLUSIONS 44 1.3.3 YEARS CONSIDERED 45 1.4 CURRENCY CONSIDERED 45 1.5 STAKEHOLDERS 45 1.6 SUMMARY OF CHANGES 46 2 RESEARCH METHODOLOGY 47 2.1 RESEARCH DATA 47 2.1.1 SECONDARY DATA 48 2.1.1.1 Key objectives of secondary research 48 2.1.1.2 Key data from secondary sources 49 2.1.2 PRIMARY DATA 49 2.1.2.1 Breakdown of primaries 50 2.1.2.2 Key objectives of primary research 50 2.2 MARKET SIZE ESTIMATION 51 2.2.1 GLOBAL MARKET ESTIMATION 51 2.2.1.1 Company revenue analysis (Bottom-up approach) 51 2.2.1.2 MnM repository analysis 53 2.2.1.3 Primary interviews 53 2.2.2 INSIGHTS FROM PRIMARY EXPERTS 54 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 54 2.3 GROWTH RATE PROJECTIONS 55 2.4 DATA TRIANGULATION 57 2.5 RESEARCH ASSUMPTIONS 58 2.6 RESEARCH LIMITATIONS 59 2.7 RISK ANALYSIS 59 3 EXECUTIVE SUMMARY 60 3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 64 3.1.1 PHARMACEUTICAL CONTRACT MANUFACTURERS 64 3.1.1.1 Capacity lock in for GLP-1 and biologics opportunities 64 3.1.1.2 Sterile fill-finish services 64 3.1.1.3 OSD differentiation and dual site sourcing 64   3.1.2 PHARMACEUTICAL COMPANIES 64 3.1.2.1 Own vs. outsourcing critical steps 64 3.1.2.2 Dual-source, multi-site supply resilience 65 3.1.3 STARTUPS AND INNOVATIVE BIOTECH FIRMS 65 3.1.3.1 Gene-to-IND platform 65 3.1.3.2 Clinical supply risk management 65 4 PREMIUM INSIGHTS 66 4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW 66 4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE AND COUNTRY, 2025 67 4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE 68 4.4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER 68 4.5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 69 4.6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EMERGING VS. DEVELOPED MARKETS 70 5 MARKET OVERVIEW 71 5.1 INTRODUCTION 71 5.2 MARKET DYNAMICS 71 5.2.1 DRIVERS 73 5.2.1.1 GLP-1 capacity crunch 73 5.2.1.2 Increasing development and manufacturing of antibody drug conjugates 74 5.2.1.3 Loss of exclusivity of blockbuster biologics 75 5.2.1.4 Increasing complexity of injectable drug formats 76 5.2.2 RESTRAINTS 77 5.2.2.1 Pricing pressure on innovator drugs 77 5.2.2.2 Growing penetration of generics and biosimilars 78 5.2.2.3 Strict regulatory compliance 78 5.2.2.4 Risk in advanced therapies pipeline 79 5.2.3 OPPORTUNITIES 79 5.2.3.1 Rising demand for cell and gene therapies 79 5.2.3.2 Growing inclination toward one-stop-shop model 82 5.2.3.3 Market expansion in emerging countries 82 5.2.3.4 Booming radiopharmaceutical and nuclear medicine segment 83 5.2.4 CHALLENGES 83 5.2.4.1 Global trade instability and insourcing 83 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 84 5.4 PRICING ANALYSIS 85 5.4.1 INDICATIVE PRICING ANALYSIS, BY SERVICE 85 5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION 86 5.4.3 COMPARISON OF CDMO PRICING MODELS 86 5.5 VALUE CHAIN ANALYSIS 87 5.6 SUPPLY CHAIN ANALYSIS 88 5.7 ECOSYSTEM ANALYSIS 91 5.7.1 MANUFACTURING SITE, EXPANSION, AND CAPEX TREND OF KEY CDMOS 93 5.8 INVESTMENT AND FUNDING SCENARIO 97 5.9 TECHNOLOGY ANALYSIS 98 5.9.1 KEY TECHNOLOGIES 98 5.9.1.1 Single-use bioprocessing systems 98 5.9.1.2 Continuous manufacturing 99 5.9.1.3 Advanced formulation technologies 99 5.9.2 COMPLEMENTARY TECHNOLOGIES 99 5.9.2.1 High-performance liquid chromatography 99 5.9.2.2 Mass spectrometry 100 5.9.2.3 Next-generation sequencing 101 5.9.2.4 Automation and robotics 101 5.9.2.5 Process analytical technology 101 5.9.3 ADJACENT TECHNOLOGIES 102 5.9.3.1 3D printing 102 5.9.3.2 Artificial intelligence and machine learning 102 5.10 PATENT ANALYSIS 103 5.11 KEY CONFERENCES AND EVENTS, 2025–2026 104 5.12 REGULATORY LANDSCAPE 106 5.12.1 REGULATORY SCENARIO 106 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108 5.13 PORTER’S FIVE FORCES ANALYSIS 112 5.13.1 BARGAINING POWER OF SUPPLIERS 113 5.13.2 BARGAINING POWER OF BUYERS 113 5.13.3 THREAT OF NEW ENTRANTS 113 5.13.4 THREAT OF SUBSTITUTES 113 5.13.5 INTENSITY OF COMPETITIVE RIVALRY 113 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 114 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 114 5.14.2 BUYING CRITERIA 114 5.15 UNMET NEEDS OF END USERS 115 5.15.1 CAPACITY AND TIMELY ACCESS 115 5.15.2 COST EFFICIENCY AND FLEXIBILITY 116 5.15.3 END-TO-END INTEGRATED SERVICES 116 5.15.4 ADVANCED MODALITY EXPERTISE 116 5.15.5 QUALITY AND REGULATORY CONSISTENCY 116 5.16 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS 116 5.17 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET 117 5.17.1 INTRODUCTION 117 5.17.2 MARKET POTENTIAL OF AI/GEN AI 117 5.17.3 AI USE CASES 118 5.17.4 KEY COMPANIES IMPLEMENTING AI/GEN AI 119 5.18 IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET 120 5.18.1 INTRODUCTION 120 5.18.2 KEY TARIFF RATES 121 5.18.3 PRICE IMPACT ANALYSIS 122 5.18.4 IMPACT ON COUNTRY/REGION 122 5.18.4.1 US 122 5.18.4.2 Europe 123 5.18.4.3 Asia Pacific 123 5.18.4.3.1 India 124 5.18.5 IMPACT ON END-USE INDUSTRIES 124 6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE 126 6.1 INTRODUCTION 127 6.2 PHARMACEUTICAL MANUFACTURING SERVICES 127 6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES 131 6.2.1.1 Rising cases of patent expiry to fuel market 131 6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES 135 6.2.2.1 Parenteral manufacturing services 139 6.2.2.1.1 Increasing demand for specialized manufacturing capabilities to support growth 139 6.2.2.2 Tablet manufacturing services 142 6.2.2.2.1 Growing domestic production capacity in emerging markets to boost market 142 6.2.2.3 Capsule manufacturing services 146 6.2.2.3.1 Rising adoption in pharmaceutical, nutraceutical, and cosmetic applications to stimulate growth 146 6.2.2.4 Oral liquid manufacturing services 149 6.2.2.4.1 Growing preference for oral liquids over powders to fuel market 149 6.2.2.5 Semi-solid manufacturing services 153 6.2.2.5.1 Rising prevalence of skin infections and burns to foster growth 153 6.2.2.6 Other FDF manufacturing services 156 6.3 DRUG DEVELOPMENT SERVICES 160 6.3.1 INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH 160   6.4 BIOLOGICS MANUFACTURING SERVICES 163 6.4.1 BIOLOGICS API MANUFACTURING SERVICES 167 6.4.1.1 Rising investments in single-use production capacities to bolster growth 167 6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES 170 6.4.2.1 Growing demand for generic medicines and biologics to fuel market 170 6.5 PACKAGING & LABELING SERVICES 174 6.5.1 INCREASING COMPLEXITY AND STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR GROWTH 174 6.6 FILL-FINISH SERVICES 177 6.6.1 SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO BOOST MARKET 177 6.7 OTHER SERVICES 181 7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE 185 7.1 INTRODUCTION 186 7.2 SMALL MOLECULES 186 7.2.1 HIGH-POTENCY SMALL MOLECULES 190 7.2.1.1 Increasing adoption of high-potency small molecules for treating oncology, rare diseases, and other diseases to aid growth 190 7.2.2 OLIGONUCLEOTIDE & SYNTHETIC PEPTIDES 194 7.2.2.1 Growing focus on next-gen therapies to drive market 194 7.2.3 RADIOPHARMACEUTICAL MOLECULES 197 7.2.3.1 Advances in isotope production, radiolabeling chemistry, and theranostic approaches to boost market 197 7.2.4 OTHER SMALL MOLECULES 201 7.3 LARGE MOLECULES 204 7.3.1 MONOCLONAL ANTIBODIES 208 7.3.1.1 Rising use of mAbs in managing cancer, autoimmune disorders, and osteoporosis to spur growth 208 7.3.2 CELL & GENE THERAPIES 212 7.3.2.1 Emerging treatments for previously untreatable genetic and rare diseases to boost market 212 7.3.3 ANTIBODY DRUG CONJUGATES 215 7.3.3.1 Growing need for precision medicines to fuel market 215 7.3.4 VACCINES 219 7.3.4.1 Growing threat of infectious disease outbreaks to drive market 219 7.3.5 THERAPEUTIC PEPTIDES & PROTEINS 222 7.3.5.1 Increasing research in genomics to support growth 222 7.3.6 OTHER LARGE MOLECULES 225   8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER 229 8.1 INTRODUCTION 230 8.2 BIG PHARMACEUTICAL COMPANIES 230 8.2.1 PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO GROWTH 230 8.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES 234 8.3.1 NEED TO SAVE IN-HOUSE DRUG MANUFACTURING COST TO FOSTER GROWTH 234 8.4 GENERIC PHARMACEUTICAL COMPANIES 238 8.4.1 FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET 238 8.5 OTHER END USERS 241 9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION 245 9.1 INTRODUCTION 246 9.2 NORTH AMERICA 246 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 247 9.2.2 US 253 9.2.2.1 High clinical trial and drug discovery activities to foster growth 253 9.2.3 CANADA 258 9.2.3.1 Favorable government support and increased focus on R&D activities to sustain growth 258 9.3 EUROPE 263 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 263 9.3.2 GERMANY 269 9.3.2.1 Free drug-pricing policy and high pharmaceutical investments to speed up growth 269 9.3.3 UK 274 9.3.3.1 Favorable R&D funding scenario to augment growth 274 9.3.4 FRANCE 278 9.3.4.1 Booming life science research and growing generics market to drive market 278 9.3.5 ITALY 283 9.3.5.1 Rising commercial drug development and increasing life science R&D to favor growth 283 9.3.6 SWITZERLAND 287 9.3.6.1 Rapid growth as global pharmaceutical manufacturing hub to drive market 287 9.3.7 POLAND 292 9.3.7.1 Universal health coverage and advanced government-supported medical infrastructure to encourage growth 292 9.3.8 SPAIN 296 9.3.8.1 Growing pharmaceutical R&D expenditure and increasing outsourcing of trial phases to boost market 296 9.3.9 REST OF EUROPE 301 9.4 ASIA PACIFIC 305 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 306 9.4.2 CHINA 312 9.4.2.1 Made in China 2025 initiative and high government drug development investments to aid growth 312 9.4.3 JAPAN 317 9.4.3.1 High geriatric population and advanced pharmaceutical research to augment growth 317 9.4.4 SOUTH KOREA 321 9.4.4.1 Increased biotech investments and developed pharma sector to propel market 321 9.4.5 INDIA 325 9.4.5.1 Favorable industrial environment and lower labor costs to drive market 325 9.4.6 AUSTRALIA 330 9.4.6.1 Strategic geographical location and stringent regulatory environment to foster growth 330 9.4.7 REST OF ASIA PACIFIC 334 9.5 LATIN AMERICA 338 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 338 9.5.2 BRAZIL 344 9.5.2.1 Rapid patient enrolment and increased focus on advanced clinical trials to expedite growth 344 9.5.3 MEXICO 348 9.5.3.1 Surge in pharmaceutical goods export to promote growth 348 9.5.4 REST OF LATIN AMERICA 352 9.6 MIDDLE EAST 357 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 357 9.6.2 GCC COUNTRIES 363 9.6.2.1 Kingdom of Saudi Arabia (KSA) 368 9.6.2.1.1 Increasing healthcare expenditure to aid growth 368 9.6.2.2 UAE 372 9.6.2.2.1 Strategic government healthcare initiatives and broader economic diversification plans to drive market 372 9.6.2.3 Rest of GCC countries 377 9.6.3 REST OF MIDDLE EAST 381 9.7 AFRICA 385 9.7.1 RISING PREVALENCE OF CHRONIC DISEASES TO FACILITATE GROWTH 385 9.7.2 MACROECONOMIC OUTLOOK OF AFRICA 385   10 COMPETITIVE LANDSCAPE 391 10.1 INTRODUCTION 391 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 391 10.3 REVENUE SHARE ANALYSIS, 2020–2024 394 10.4 MARKET SHARE ANALYSIS, 2024 395 10.5 COMPANY VALUATION AND FINANCIAL METRICS 398 10.6 BRAND/SERVICE COMPARISON 399 10.6.1 THERMO FISHER SCIENTIFIC INC. 400 10.6.2 LONZA 400 10.6.3 WUXI BIOLOGICS AND WUXI APPTEC 400 10.6.4 CATALENT, INC. 400 10.6.5 SAMSUNG BIOLOGICS 400 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 401 10.7.1 STARS 401 10.7.2 EMERGING LEADERS 401 10.7.3 PERVASIVE PLAYERS 401 10.7.4 PARTICIPANTS 401 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 403 10.7.5.1 Company footprint 403 10.7.5.2 Region footprint 404 10.7.5.3 Service footprint 405 10.7.5.4 Molecule footprint 406 10.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 408 10.8.1 PROGRESSIVE COMPANIES 408 10.8.2 RESPONSIVE COMPANIES 408 10.8.3 DYNAMIC COMPANIES 408 10.8.4 STARTING BLOCKS 408 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 410 10.8.5.1 Detailed list of key startups/SMEs 410 10.8.5.2 Competitive benchmarking of key startups/SMEs 411 10.9 COMPETITIVE SCENARIO 412 10.9.1 SERVICE LAUNCHES 412 10.9.2 DEALS 413 10.9.3 EXPANSIONS 416 11 COMPANY PROFILES 419 11.1 KEY PLAYERS 419 11.1.1 THERMO FISHER SCIENTIFIC INC. 419 11.1.1.1 Business overview 419 11.1.1.2 Services offered 421 11.1.1.3 Recent developments 422 11.1.1.3.1 Service launches 422 11.1.1.3.2 Deals 422 11.1.1.4 MnM view 423 11.1.1.4.1 Key strengths 423 11.1.1.4.2 Strategic choices 423 11.1.1.4.3 Weaknesses and competitive threats 423 11.1.2 LONZA 424 11.1.2.1 Business overview 424 11.1.2.2 Services offered 426 11.1.2.3 Recent developments 427 11.1.2.3.1 Deals 427 11.1.2.3.2 Expansions 429 11.1.2.4 MnM view 431 11.1.2.4.1 Key strengths 431 11.1.2.4.2 Strategic choices 431 11.1.2.4.3 Weaknesses and competitive threats 431 11.1.3 CATALENT, INC. 432 11.1.3.1 Business overview 432 11.1.3.2 Services offered 433 11.1.3.3 Recent developments 435 11.1.3.3.1 Service launches 435 11.1.3.3.2 Deals 436 11.1.3.3.3 Expansions 437 11.1.3.4 MnM view 439 11.1.3.4.1 Key strengths 439 11.1.3.4.2 Strategic choices 439 11.1.3.4.3 Weaknesses and competitive threats 439 11.1.4 WUXI APPTEC 440 11.1.4.1 Business overview 440 11.1.4.2 Services offered 441 11.1.4.3 Recent developments 442 11.1.4.3.1 Deals 442 11.1.4.3.2 Expansions 442 11.1.4.4 MnM view 443 11.1.4.4.1 Key strengths 443 11.1.4.4.2 Strategic choices 443 11.1.4.4.3 Weaknesses and competitive threats 443 11.1.5 WUXI BIOLOGICS 444 11.1.5.1 Business overview 444 11.1.5.2 Services offered 445 11.1.5.3 Recent developments 446 11.1.5.3.1 Service launches 446 11.1.5.3.2 Deals 446 11.1.5.3.3 Expansions 447 11.1.5.3.4 Other developments 447 11.1.6 SAMSUNG BIOLOGICS 448 11.1.6.1 Business overview 448 11.1.6.2 Services offered 450 11.1.6.3 Recent developments 450 11.1.6.3.1 Service launches 450 11.1.6.3.2 Deals 451 11.1.6.3.3 Expansions 452 11.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 453 11.1.7.1 Business overview 453 11.1.7.2 Services offered 455 11.1.7.3 Recent developments 455 11.1.7.3.1 Deals 455 11.1.7.3.2 Expansions 456 11.1.7.3.3 Other developments 456 11.1.8 EVONIK 457 11.1.8.1 Business overview 457 11.1.8.2 Services offered 458 11.1.8.3 Recent developments 459 11.1.8.3.1 Deals 459 11.1.8.3.2 Expansions 459 11.1.9 FUJIFILM HOLDINGS CORPORATION 460 11.1.9.1 Business overview 460 11.1.9.2 Services offered 461 11.1.9.3 Recent developments 463 11.1.9.3.1 Deals 463 11.1.9.3.2 Expansions 464 11.1.10 ABBVIE INC. 466 11.1.10.1 Business overview 466 11.1.10.2 Services offered 467 11.1.10.3 Recent developments 468 11.1.10.3.1 Deals 468 11.1.10.3.2 Expansions 469 11.1.11 SIEGFRIED HOLDING AG 470 11.1.11.1 Business overview 470 11.1.11.2 Services offered 471 11.1.11.3 Recent developments 472 11.1.11.3.1 Deals 472 11.1.11.3.2 Expansions 473   11.1.12 MERCK KGAA 474 11.1.12.1 Business overview 474 11.1.12.2 Services offered 476 11.1.12.3 Recent developments 476 11.1.12.3.1 Deals 476 11.1.12.3.2 Expansions 477 11.1.13 ALMAC GROUP 478 11.1.13.1 Business overview 478 11.1.13.2 Services offered 479 11.1.13.3 Recent developments 480 11.1.13.3.1 Deals 480 11.1.13.3.2 Expansions 481 11.1.14 CHARLES RIVER LABORATORIES 482 11.1.14.1 Business overview 482 11.1.14.2 Services offered 483 11.1.14.3 Recent developments 483 11.1.14.3.1 Deals 483 11.1.14.3.2 Expansions 484 11.1.15 ASYMCHEM INC. 485 11.1.15.1 Business overview 485 11.1.15.2 Services offered 486 11.1.15.3 Recent developments 487 11.1.15.3.1 Deals 487 11.1.15.3.2 Expansions 487 11.1.16 VETTER 488 11.1.16.1 Business overview 488 11.1.16.2 Services offered 489 11.1.16.3 Recent developments 489 11.1.16.3.1 Service launches 489 11.1.16.3.2 Deals 490 11.1.16.3.3 Expansions 490 11.1.17 ALCAMI CORPORATION 491 11.1.17.1 Business overview 491 11.1.17.2 Services offered 491 11.1.17.3 Recent developments 492 11.1.17.3.1 Deals 492 11.1.17.3.2 Expansions 492 11.1.18 EUROFINS SCIENTIFIC 493 11.1.18.1 Business overview 493 11.1.18.2 Services offered 494 11.1.18.3 Recent developments 495 11.1.18.3.1 Expansions 495 11.2 OTHER PLAYERS 496 11.2.1 PIRAMAL PHARMA SOLUTIONS 496 11.2.2 SYNGENE INTERNATIONAL LIMITED 497 11.2.3 CAMBREX CORPORATION 498 11.2.4 JUBILANT PHARMANOVA LIMITED 499 11.2.5 YUHAN CORPORATION 500 11.2.6 PIERRE FABRE LABORATORIES 501 11.2.7 PFIZER CENTREONE 502 11.2.8 DELPHARM 503 11.2.9 FRONTAGE LABS 504 11.2.10 SHARP SERVICES, LLC 505 11.2.11 GRAND RIVER ASEPTIC MANUFACTURING 506 11.2.12 RECIPHARM AB 507 11.2.13 PCI PHARMA SERVICES 508 11.2.14 CURIA GLOBAL, INC. 509 11.2.15 SIMTRA BIOPHARMA SOLUTIONS 510 11.2.16 PORTON 510 11.2.17 MABPLEX INTERNATIONAL CO. LTD. 511 11.2.18 CELLARES 512 12 APPENDIX 513 12.1 DISCUSSION GUIDE 513 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 517 12.3 CUSTOMIZATION OPTIONS 519 12.4 RELATED REPORTS 520 12.5 AUTHOR DETAILS 521

TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS AND EXCLUSIONS 44 TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 57 TABLE 3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS 59 TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 72 TABLE 5 GLP-1 PIPELINE, EXPECTED LAUNCH BY 2030 73 TABLE 6 ADC PIPELINE, EXPECTED LAUNCH BY 2030 74 TABLE 7 IMPENDING AND ONGOING PATENT EXPIRIES OF BLOCKBUSTER BIOLOGICS, 2023–2035 75 TABLE 8 LIST OF RECENTLY APPROVED INJECTABLES, 2022–2024 77 TABLE 9 CELL & GENE THERAPY-SPECIFIC CDMO EXPANSIONS, 2023–2025 80 TABLE 10 CELL & GENE THERAPY PIPELINE, EXPECTED LAUNCH BY 2030 80 TABLE 11 INDICATIVE PRICING ANALYSIS, BY SERVICE 85 TABLE 12 INDICATIVE PRICING ANALYSIS, BY REGION 86 TABLE 13 PRICING MODELS FOR CDMO SERVICES 86 TABLE 14 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN SUPPLY CHAIN 89 TABLE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 91 TABLE 16 MANUFACTURING SITES OF KEY CDMOS 93 TABLE 17 LIST OF SITE EXPANSIONS FOR KEY CDMOS, 2023–2025 95 TABLE 18 CAPEX FOR SELECTED PUBLICLY LISTED KEY CDMOS, 2021–2024 (USD MILLION) 96 TABLE 19 NUMBER OF PATENTS FILED IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024 103 TABLE 20 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 105 TABLE 21 REGULATORY SCENARIO, BY COUNTRY 106 TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108 TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109 TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110 TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111 TABLE 26 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111 TABLE 27 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111 TABLE 28 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 112 TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%) 114 TABLE 30 BUYING CRITERIA FOR PHARMACEUTICAL CONTRACT MANUFACTURING, BY END USER 115 TABLE 31 US-ADJUSTED RECIPROCAL TARIFF RATES 121 TABLE 32 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 127 TABLE 33 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 128 TABLE 34 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 128 TABLE 35 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 129 TABLE 36 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 129 TABLE 37 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 130 TABLE 38 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 130 TABLE 39 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 131 TABLE 40 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 131 TABLE 41 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION) 132 TABLE 42 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 132 TABLE 43 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 133 TABLE 44 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 133 TABLE 45 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 134 TABLE 46 MIDDLE EAST: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION) 134 TABLE 47 GCC COUNTRIES: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 134 TABLE 48 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030(USD BILLION) 135 TABLE 49 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION) 136 TABLE 50 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 136 TABLE 51 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 137 TABLE 52 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 137 TABLE 53 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 138 TABLE 54 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION) 138 TABLE 55 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION) 138 TABLE 56 PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 139 TABLE 57 NORTH AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 140 TABLE 58 EUROPE: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 140 TABLE 59 ASIA PACIFIC: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 141 TABLE 60 LATIN AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 141 TABLE 61 MIDDLE EAST: PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 142 TABLE 62 GCC COUNTRIES: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 142 TABLE 63 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 143 TABLE 64 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 143 TABLE 65 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 144 TABLE 66 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 144 TABLE 67 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 145 TABLE 68 MIDDLE EAST: TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 145 TABLE 69 GCC COUNTRIES: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 145 TABLE 70 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 146 TABLE 71 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 147 TABLE 72 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 147 TABLE 73 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 148 TABLE 74 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 148 TABLE 75 MIDDLE EAST: CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 149 TABLE 76 GCC COUNTRIES: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 149 TABLE 77 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 150 TABLE 78 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 150 TABLE 79 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 151 TABLE 80 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 151 TABLE 81 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 152 TABLE 82 MIDDLE EAST: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 152 TABLE 83 GCC COUNTRIES: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 152 TABLE 84 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 153 TABLE 85 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 154 TABLE 86 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 154 TABLE 87 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 155 TABLE 88 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 155 TABLE 89 MIDDLE EAST: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 156 TABLE 90 GCC COUNTRIES: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 156 TABLE 91 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 157 TABLE 92 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 157 TABLE 93 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 158 TABLE 94 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 158 TABLE 95 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 159 TABLE 96 MIDDLE EAST: OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 159 TABLE 97 GCC COUNTRIES: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 159 TABLE 98 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION) 160 TABLE 99 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 161 TABLE 100 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 161 TABLE 101 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 162 TABLE 102 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 162 TABLE 103 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION) 162 TABLE 104 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 163 TABLE 105 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 164 TABLE 106 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION) 164 TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 164 TABLE 108 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 165 TABLE 109 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 165 TABLE 110 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 166 TABLE 111 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION) 166 TABLE 112 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 166 TABLE 113 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION) 167 TABLE 114 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 168 TABLE 115 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 168 TABLE 116 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 169 TABLE 117 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 169 TABLE 118 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION) 170 TABLE 119 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 170 TABLE 120 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION) 171 TABLE 121 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 171 TABLE 122 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 172 TABLE 123 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 172 TABLE 124 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 173 TABLE 125 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION) 173 TABLE 126 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 173 TABLE 127 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION) 174 TABLE 128 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 175 TABLE 129 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 175 TABLE 130 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 176 TABLE 131 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 176 TABLE 132 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION) 176 TABLE 133 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 177 TABLE 134 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION) 178 TABLE 135 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 178 TABLE 136 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 179 TABLE 137 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 179 TABLE 138 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 180 TABLE 139 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL- FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION) 180 TABLE 140 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 180 TABLE 141 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION) 181 TABLE 142 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 182 TABLE 143 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 182 TABLE 144 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 183 TABLE 145 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 183 TABLE 146 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION) 183 TABLE 147 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 184 TABLE 148 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 186 TABLE 149 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 187 TABLE 150 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION) 187 TABLE 151 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 188 TABLE 152 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 188 TABLE 153 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 189 TABLE 154 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 189 TABLE 155 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION) 190 TABLE 156 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 190 TABLE 157 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION) 191 TABLE 158 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 191 TABLE 159 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 192 TABLE 160 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 192 TABLE 161 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 193 TABLE 162 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION) 193 TABLE 163 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 193 TABLE 164 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION, 2023–2030 (USD BILLION) 194 TABLE 165 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION) 195 TABLE 166 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION) 195 TABLE 167 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION) 196 TABLE 168 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION) 196 TABLE 169 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION, 2023–2030 (USD BILLION) 197 TABLE 170 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION) 197 TABLE 171 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION) 198 TABLE 172 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 198 TABLE 173 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 199 TABLE 174 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 199 TABLE 175 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 200 TABLE 176 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION) 200 TABLE 177 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 200 TABLE 178 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION) 201 TABLE 179 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 202 TABLE 180 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 202 TABLE 181 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 203 TABLE 182 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 203 TABLE 183 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION) 204 TABLE 184 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 204 TABLE 185 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 205 TABLE 186 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION) 205 TABLE 187 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 206 TABLE 188 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 206 TABLE 189 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 207 TABLE 190 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 207 TABLE 191 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION) 208 TABLE 192 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 208 TABLE 193 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION) 209 TABLE 194 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 209 TABLE 195 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 210 TABLE 196 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 210 TABLE 197 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 211 TABLE 198 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION) 211 TABLE 199 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 211 TABLE 200 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION) 212 TABLE 201 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION) 213 TABLE 202 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION) 213 TABLE 203 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION) 214 TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION) 214 TABLE 205 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION) 215 TABLE 206 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION) 215 TABLE 207 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION) 216 TABLE 208 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION) 216 TABLE 209 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION) 217 TABLE 210 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION) 217 TABLE 211 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION) 218 TABLE 212 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION) 218 TABLE 213 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION) 218 TABLE 214 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD BILLION) 219 TABLE 215 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 219 TABLE 216 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 220 TABLE 217 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 220 TABLE 218 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 221 TABLE 219 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD BILLION) 221 TABLE 220 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 221 TABLE 221 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION) 222 TABLE 222 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 223 TABLE 223 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 223 TABLE 224 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 224 TABLE 225 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 224 TABLE 226 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION) 225 TABLE 227 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 225 TABLE 228 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION) 226 TABLE 229 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 226 TABLE 230 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 227 TABLE 231 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 227 TABLE 232 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 228 TABLE 233 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION) 228 TABLE 234 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION) 228 TABLE 235 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 230 TABLE 236 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION) 231 TABLE 237 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 232 TABLE 238 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 232 TABLE 239 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 233 TABLE 240 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 233 TABLE 241 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION) 233 TABLE 242 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 234 TABLE 243 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION) 235 TABLE 244 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 235 TABLE 245 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 236 TABLE 246 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 236 TABLE 247 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 237 TABLE 248 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION) 237 TABLE 249 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 237 TABLE 250 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION) 238 TABLE 251 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 239 TABLE 252 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 239 TABLE 253 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 240 TABLE 254 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 240 TABLE 255 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION) 240 TABLE 256 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION) 241 TABLE 257 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION) 242 TABLE 258 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 242 TABLE 259 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 243 TABLE 260 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 243 TABLE 261 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 244 TABLE 262 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION) 244 TABLE 263 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 244 TABLE 264 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD BILLION) 246 TABLE 265 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 248 TABLE 266 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 248 TABLE 267 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 249 TABLE 268 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 249 TABLE 269 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 250 TABLE 270 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 250 TABLE 271 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 251 TABLE 272 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 251 TABLE 273 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 252 TABLE 274 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 252 TABLE 275 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 254 TABLE 276 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 254 TABLE 277 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 255 TABLE 278 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 255 TABLE 279 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 256 TABLE 280 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 256 TABLE 281 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 257 TABLE 282 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 257 TABLE 283 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 259 TABLE 284 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 259 TABLE 285 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 260 TABLE 286 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 260 TABLE 287 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 261 TABLE 288 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 261 TABLE 289 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 262 TABLE 290 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 262 TABLE 291 EUROPE: KEY MACROECONOMIC INDICATORS 264 TABLE 292 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 264 TABLE 293 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 265 TABLE 294 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 265 TABLE 295 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 266 TABLE 296 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 266 TABLE 297 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 267 TABLE 298 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 267 TABLE 299 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 268 TABLE 300 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 268 TABLE 301 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 270 TABLE 302 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 270 TABLE 303 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 271 TABLE 304 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 271 TABLE 305 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 272 TABLE 306 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 272 TABLE 307 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 273 TABLE 308 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 273 TABLE 309 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 274 TABLE 310 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 275 TABLE 311 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 275 TABLE 312 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 276 TABLE 313 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 276 TABLE 314 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 277 TABLE 315 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 277 TABLE 316 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 278 TABLE 317 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 279 TABLE 318 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 279 TABLE 319 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 280 TABLE 320 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 280 TABLE 321 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 281 TABLE 322 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 281 TABLE 323 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 282 TABLE 324 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 282 TABLE 325 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 283 TABLE 326 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 284 TABLE 327 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 284 TABLE 328 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 285 TABLE 329 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 285 TABLE 330 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 286 TABLE 331 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 286 TABLE 332 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 287 TABLE 333 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 288 TABLE 334 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 288 TABLE 335 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 289 TABLE 336 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 289 TABLE 337 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 290 TABLE 338 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 290 TABLE 339 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 291 TABLE 340 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 291 TABLE 341 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 292 TABLE 342 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 293 TABLE 343 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 293 TABLE 344 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 294 TABLE 345 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 294 TABLE 346 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 295 TABLE 347 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 295 TABLE 348 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 296 TABLE 349 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 297 TABLE 350 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 297 TABLE 351 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 298 TABLE 352 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 298 TABLE 353 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 299 TABLE 354 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 299 TABLE 355 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 300 TABLE 356 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 300 TABLE 357 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 301 TABLE 358 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 302 TABLE 359 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 302 TABLE 360 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 303 TABLE 361 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 303 TABLE 362 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 304 TABLE 363 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 304 TABLE 364 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 305 TABLE 365 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 307 TABLE 366 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 307 TABLE 367 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 308 TABLE 368 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 308 TABLE 369 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 309 TABLE 370 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 309 TABLE 371 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 310 TABLE 372 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 310 TABLE 373 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 311 TABLE 374 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 311 TABLE 375 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 313 TABLE 376 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 313 TABLE 377 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 314 TABLE 378 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 314 TABLE 379 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 315 TABLE 380 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 315 TABLE 381 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 316 TABLE 382 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 316 TABLE 383 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 317 TABLE 384 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 318 TABLE 385 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 318 TABLE 386 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 319 TABLE 387 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 319 TABLE 388 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 319 TABLE 389 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 320 TABLE 390 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 320 TABLE 391 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 321 TABLE 392 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 322 TABLE 393 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 322 TABLE 394 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 323 TABLE 395 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 323 TABLE 396 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 324 TABLE 397 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 324 TABLE 398 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 325 TABLE 399 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 326 TABLE 400 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 326 TABLE 401 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 327 TABLE 402 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 327 TABLE 403 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 328 TABLE 404 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 328 TABLE 405 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 329 TABLE 406 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 329 TABLE 407 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 330 TABLE 408 AUSTRALIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 331 TABLE 409 AUSTRALIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 331 TABLE 410 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 332 TABLE 411 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 332 TABLE 412 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 332 TABLE 413 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 333 TABLE 414 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 333 TABLE 415 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 334 TABLE 416 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 335 TABLE 417 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 335 TABLE 418 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 336 TABLE 419 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 336 TABLE 420 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 336 TABLE 421 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 337 TABLE 422 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 337 TABLE 423 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 339 TABLE 424 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 339 TABLE 425 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 340 TABLE 426 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 340 TABLE 427 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 341 TABLE 428 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 341 TABLE 429 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 342 TABLE 430 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 342 TABLE 431 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 343 TABLE 432 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 343 TABLE 433 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 344 TABLE 434 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 345 TABLE 435 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 345 TABLE 436 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 346 TABLE 437 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 346 TABLE 438 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 346 TABLE 439 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 347 TABLE 440 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 347 TABLE 441 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 348 TABLE 442 MEXICO: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 349 TABLE 443 MEXICO: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 349 TABLE 444 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 350 TABLE 445 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 350 TABLE 446 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 351 TABLE 447 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 351 TABLE 448 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 352 TABLE 449 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 353 TABLE 450 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 353 TABLE 451 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 354 TABLE 452 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 354 TABLE 453 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 355 TABLE 454 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 355 TABLE 455 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 356 TABLE 456 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 356 TABLE 457 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 358 TABLE 458 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD BILLION) 359 TABLE 459 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 359 TABLE 460 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 360 TABLE 461 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 360 TABLE 462 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 361 TABLE 463 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 361 TABLE 464 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 361 TABLE 465 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 362 TABLE 466 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 362 TABLE 467 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 363 TABLE 468 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 364 TABLE 469 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 364 TABLE 470 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 365 TABLE 471 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 365 TABLE 472 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 366 TABLE 473 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 366 TABLE 474 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 367 TABLE 475 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 367 TABLE 476 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 368 TABLE 477 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 369 TABLE 478 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 369 TABLE 479 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 370 TABLE 480 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 370 TABLE 481 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 370 TABLE 482 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 371 TABLE 483 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 371 TABLE 484 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 373 TABLE 485 UAE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 373 TABLE 486 UAE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 374 TABLE 487 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 374 TABLE 488 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 375 TABLE 489 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 375 TABLE 490 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 376 TABLE 491 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 376 TABLE 492 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 377 TABLE 493 REST OF GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 378 TABLE 494 REST OF GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 378 TABLE 495 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 379 TABLE 496 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 379 TABLE 497 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 379 TABLE 498 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 380 TABLE 499 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 380 TABLE 500 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 381 TABLE 501 REST OF MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 382 TABLE 502 REST OF MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 382 TABLE 503 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 383 TABLE 504 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 383 TABLE 505 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 383 TABLE 506 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 384 TABLE 507 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) 384 TABLE 508 AFRICA: KEY MACROECONOMIC INDICATORS 386 TABLE 509 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION) 386 TABLE 510 AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 387 TABLE 511 AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 387 TABLE 512 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 388 TABLE 513 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 388 TABLE 514 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 389 TABLE 515 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 389 TABLE 516 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) S 390 TABLE 517 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, JANUARY 2022–AUGUST 2025 392 TABLE 518 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION 396 TABLE 519 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGION FOOTPRINT 404 TABLE 520 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE FOOTPRINT 405 TABLE 521 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: MOLECULE FOOTPRINT 406 TABLE 522 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 410 TABLE 523 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 411 TABLE 524 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2022–JULY 2025 412 TABLE 525 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2022–JULY 2025 413 TABLE 526 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EXPANSIONS, JANUARY 2022–JULY 2025 416 TABLE 527 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 419 TABLE 528 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 421 TABLE 529 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2022–JULY 2025 422 TABLE 530 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JULY 2025 422 TABLE 531 LONZA: COMPANY OVERVIEW 424 TABLE 532 LONZA: SERVICES OFFERED 426 TABLE 533 LONZA: DEALS, JANUARY 2022–JULY 2025 427 TABLE 534 LONZA: EXPANSIONS, JANUARY 2022–JULY 2025 429 TABLE 535 CATALENT, INC.: COMPANY OVERVIEW 432 TABLE 536 CATALENT, INC.: SERVICES OFFERED 433 TABLE 537 CATALENT, INC.: SERVICE LAUNCHES, JANUARY 2022–JULY 2025 435 TABLE 538 CATALENT, INC.: DEALS, JANUARY 2022–JULY 2025 436 TABLE 539 CATALENT, INC.: EXPANSIONS, JANUARY 2022–JULY 2025 437 TABLE 540 WUXI APPTEC: COMPANY OVERVIEW 440 TABLE 541 WUXI APPTEC: SERVICES OFFERED 441 TABLE 542 WUXI APPTEC: DEALS, JANUARY 2022–JULY 2025 442 TABLE 543 WUXI APPTEC: EXPANSIONS, JANUARY 2022–JULY 2025 442 TABLE 544 WUXI BIOLOGICS: COMPANY OVERVIEW 444 TABLE 545 WUXI BIOLOGICS: SERVICES OFFERED 445 TABLE 546 WUXI BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JULY 2025 446 TABLE 547 WUXI BIOLOGICS: DEALS, JANUARY 2022–JULY 2025 446 TABLE 548 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022–JULY 2025 447 TABLE 549 WUXI BIOLOGICS: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025 447 TABLE 550 SAMSUNG BIOLOGICS: COMPANY OVERVIEW 448 TABLE 551 SAMSUNG BIOLOGICS: SERVICES OFFERED 450 TABLE 552 SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025 450 TABLE 553 SAMSUNG BIOLOGICS: DEALS, JANUARY 2022–JULY 2025 451 TABLE 554 SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2022–JULY 2025 452 TABLE 555 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 453 TABLE 556 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SERVICES OFFERED 455 TABLE 557 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022–JULY 2025 455 TABLE 558 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022–JULY 2025 456 TABLE 559 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025 456 TABLE 560 EVONIK: COMPANY OVERVIEW 457 TABLE 561 EVONIK: SERVICES OFFERED 458 TABLE 562 EVONIK: DEALS, JANUARY 2022–JULY 2025 459 TABLE 563 EVONIK: EXPANSIONS, JANUARY 2022–JULY 2025 459 TABLE 564 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW 460 TABLE 565 FUJIFILM HOLDINGS CORPORATION: SERVICES OFFERED 461 TABLE 566 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–JULY 2025 463 TABLE 567 FUJIFILM HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2022–JULY 2025 464 TABLE 568 ABBVIE INC.: COMPANY OVERVIEW 466 TABLE 569 ABBVIE INC.: SERVICES OFFERED 467 TABLE 570 ABBVIE INC.: DEALS, JANUARY 2022–JULY 2025 468 TABLE 571 ABBVIE INC.: EXPANSIONS, JANUARY 2022–JULY 2025 469 TABLE 572 SIEGFRIED HOLDING AG: COMPANY OVERVIEW 470 TABLE 573 SIEGFRIED HOLDING AG: SERVICES OFFERED 471 TABLE 574 SIEGFRIED HOLDING AG: DEALS, JANUARY 2022–JULY 2025 472 TABLE 575 SIEGFRIED HOLDING AG: EXPANSIONS, JANUARY 2022–JULY 2025 473 TABLE 576 MERCK KGAA: COMPANY OVERVIEW 474 TABLE 577 MERCK KGAA: SERVICES OFFERED 476 TABLE 578 MERCK KGAA: DEALS, JANUARY 2022–JULY 2025 476 TABLE 579 MERCK KGAA: EXPANSIONS, JANUARY 2022–JULY 2025 477 TABLE 580 ALMAC GROUP: COMPANY OVERVIEW 478 TABLE 581 ALMAC GROUP: SERVICES OFFERED 479 TABLE 582 ALMAC GROUP: DEALS, JANUARY 2022–JULY 2025 480 TABLE 583 ALMAC GROUP: EXPANSIONS, JANUARY 2022–JULY 2025 481 TABLE 584 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 482 TABLE 585 CHARLES RIVER LABORATORIES: SERVICES OFFERED 483 TABLE 586 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–JULY 2025 483 TABLE 587 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–JULY 2025 484 TABLE 588 ASYMCHEM INC.: COMPANY OVERVIEW 485 TABLE 589 ASYMCHEM INC.: SERVICES OFFERED 486 TABLE 590 ASYMCHEM INC.: DEALS, JANUARY 2022–JULY 2025 487 TABLE 591 ASYMCHEM INC.: EXPANSIONS, JANUARY 2022–JULY 2025 487 TABLE 592 VETTER: COMPANY OVERVIEW 488 TABLE 593 VETTER: SERVICES OFFERED 489 TABLE 594 VETTER: SERVICE LAUNCHES, JANUARY 2022–JULY 2025 489 TABLE 595 VETTER: DEALS, JANUARY 2022–JULY 2025 490 TABLE 596 VETTER: EXPANSIONS, JANUARY 2022–JULY 2025 490 TABLE 597 ALCAMI CORPORATION: COMPANY OVERVIEW 491 TABLE 598 ALCAMI CORPORATION: SERVICES OFFERED 491 TABLE 599 ALCAMI CORPORATION: DEALS, JANUARY 2022–JULY 2025 492 TABLE 600 ALCAMI CORPORATION: EXPANSIONS, JANUARY 2022–JULY 2025 492 TABLE 601 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 493 TABLE 602 EUROFINS SCIENTIFIC: SERVICES OFFERED 494 TABLE 603 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–JUNE 2025 495 TABLE 604 PIRAMAL PHARMA SOLUTIONS: COMPANY OVERVIEW 496 TABLE 605 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW 497 TABLE 606 CAMBREX CORPORATION: COMPANY OVERVIEW 498 TABLE 607 JUBILANT PHARMANOVA LIMITED: COMPANY OVERVIEW 499 TABLE 608 YUHAN CORPORATION: COMPANY OVERVIEW 500 TABLE 609 PIERRE FABRE LABORATORIES: COMPANY OVERVIEW 501 TABLE 610 PFIZER CENTREONE: COMPANY OVERVIEW 502 TABLE 611 DELPHARM: COMPANY OVERVIEW 503 TABLE 612 FRONTAGE LABS: COMPANY OVERVIEW 504 TABLE 613 SHARP SERVICES, LLC: COMPANY OVERVIEW 505 TABLE 614 GRAND RIVER ASEPTIC MANUFACTURING: COMPANY OVERVIEW 506 TABLE 615 RECIPHARM AB: COMPANY OVERVIEW 507 TABLE 616 PCI PHARMA SERVICES: COMPANY OVERVIEW 508 TABLE 617 CURIA GLOBAL, INC.: COMPANY OVERVIEW 509 TABLE 618 SIMTRA BIOPHARMA SOLUTIONS: COMPANY OVERVIEW 510 TABLE 619 PORTON: COMPANY OVERVIEW 510 TABLE 620 MABPLEX INTERNATIONAL CO. LTD.: COMPANY OVERVIEW 511 TABLE 621 CELLARES: COMPANY OVERVIEW 512 FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION AND REGIONAL SCOPE 43 FIGURE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: YEARS CONSIDERED 45 FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH DESIGN 47 FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY DATA FROM SECONDARY SOURCES 49 FIGURE 5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 50 FIGURE 6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 51 FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2024 52 FIGURE 8 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC., 2024 52 FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE VALIDATION FROM PRIMARY SOURCES 54 FIGURE 10 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: TOP-DOWN APPROACH 55 FIGURE 11 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS 56 FIGURE 12 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DATA TRIANGULATION 58 FIGURE 13 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2025 VS. 2030 (USD BILLION) 60 FIGURE 14 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD BILLION) 61 FIGURE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2025 VS. 2030 (USD BILLION) 61 FIGURE 16 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2025 VS. 2030 (USD BILLION) 62 FIGURE 17 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2025–2030 63 FIGURE 18 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET 66 FIGURE 19 PHARMACEUTICAL MANUFACTURING SERVICES AND US TO LEAD NORTH AMERICAN MARKET IN 2025 67 FIGURE 20 SMALL MOLECULES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 68 FIGURE 21 BIG PHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 68 FIGURE 22 CHINA TO HAVE LARGEST MARKET DURING FORECAST PERIOD 69 FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 70 FIGURE 24 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 71 FIGURE 25 NEW REVENUE POCKETS FOR PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET 84 FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS 88 FIGURE 27 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SUPPLY CHAIN ANALYSIS 88 FIGURE 28 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM ANALYSIS 91 FIGURE 29 INVESTMENT AND FUNDING SCENARIO, 2023–2024 97 FIGURE 30 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 104 FIGURE 31 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 112 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY SERVICE 114 FIGURE 33 KEY BUYING CRITERIA FOR END USERS 115 FIGURE 34 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2020–2025 117 FIGURE 35 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: AI USE CASES 118 FIGURE 36 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT 247 FIGURE 37 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT 306 FIGURE 39 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 396 FIGURE 40 EV/EBITDA OF KEY VENDORS 398 FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 398 FIGURE 42 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/SERVICE COMPARISON 399 FIGURE 43 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 402 FIGURE 44 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT 403 FIGURE 45 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 409 FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 420 FIGURE 47 LONZA: COMPANY SNAPSHOT (2024) 425 FIGURE 48 CATALENT, INC.: COMPANY SNAPSHOT (2023) 433 FIGURE 49 WUXI APPTEC: COMPANY SNAPSHOT (2024) 441 FIGURE 50 WUXI BIOLOGICS: COMPANY SNAPSHOT (2024) 445 FIGURE 51 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2024) 449 FIGURE 52 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024) 454 FIGURE 53 EVONIK: COMPANY SNAPSHOT (2024) 458 FIGURE 54 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024) 461 FIGURE 55 ABBVIE INC.: COMPANY SNAPSHOT (2024) 467 FIGURE 56 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2024) 471 FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT (2024) 475 FIGURE 58 ALMAC GROUP: COMPANY SNAPSHOT (2024) 478 FIGURE 59 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024) 482 FIGURE 60 ASYMCHEM INC.: COMPANY SNAPSHOT (2024) 486 FIGURE 61 VETTER: COMPANY SNAPSHOT (2024) 488 FIGURE 62 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 494